|
[1]
|
Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer[J]. J Natl Cancer Inst, 2009, 101 : 1308-1324. doi: 10.1093/jnci/djp280 |
|
[2]
|
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351:337-345. doi: 10.1056/NEJMoa033025 |
|
[3]
|
Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy[J]. Ann Oncol, 2008, 19:92-98. doi: 10.1093/annonc/mdm399 |
|
[4]
|
McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Ra.MEK/ERK pathway in cell growth, malignant transformation and drug resistance[J]. Biochim Biophys Acta, 2007, 1773:1263-1284. doi: 10.1016/j.bbamcr.2006.10.001 |
|
[5]
|
McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance[J]. Adv Enzyme Regul, 2006, 46:249-279. doi: 10.1016/j.advenzreg.2006.01.004 |
|
[6]
|
Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab[J]. J Clin Oncol, 2008, 26:374-379. doi: 10.1200/JCO.2007.12.5906 |
|
[7]
|
Jonker DJ, O'Gallaghan GJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer[J]. N Engl J Med, 2007, 357:2040-2048. doi: 10.1056/NEJMoa071834 |
|
[8]
|
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med, 2008, 359: 1757-1765. doi: 10.1056/NEJMoa0804385 |
|
[9]
|
Bokemeyer C, Bondarenko I, Hartmann JT, et al. K-RAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab : the OPUS experience (abstract)[J]. J Clin Oncol, 2008, 26:178s. |
|
[10]
|
Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360: 1408-1417. doi: 10.1056/NEJMoa0805019 |
|
[11]
|
蒲兴祥, 邓艳红, 徐菲, 等.KRAS突变对晚期结直肠癌C225联合化疗疗效的影响[J].中华胃肠外科杂志, 2008, 12:594-597. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwcwkzz200906016 |
|
[12]
|
庄荣源, 刘天舒, 周宇红, 等.西妥昔单抗联合化疗治疗转移性结直肠癌疗效与KRAS状态的关系[J].中国癌症杂志, 2009, 19:943-946. doi: 10.3969/j.issn.1007-3639.2009.12.012 |
|
[13]
|
De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab[J]. Ann Oncol, 2008, 19: 508-515. doi: 10.1093/annonc/mdm496 |
|
[14]
|
Di Nicolantonio F, Martini M, Molinari F, et al. A wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26:5705-5712. doi: 10.1200/JCO.2008.18.0786 |
|
[15]
|
Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies[J]. Cancer Res, 2009, 69: 1851-1857. doi: 10.1158/0008-5472.CAN-08-2466 |
|
[16]
|
Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients[J]. Ann Oncol, 2009, 20:84-90. doi: 10.1093/annonc/mdn541 |
|
[17]
|
Razis E, Briasoulis E, Vrettou E, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study[J]. BMC Cancer, 2008, 8:234. doi: 10.1186/1471-2407-8-234 |
|
[18]
|
Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma :an immunohistochemical and chromogenic in situ hybridization study[J].Mod Pathol, 2005, 18: 1350-1356. doi: 10.1038/modpathol.3800417 |
|
[19]
|
Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies[J]. J Clin Oncol, 2004, 22: 4772-4778. doi: 10.1200/JCO.2004.00.117 |
|
[20]
|
Francoual M, Etienne-Grimaldi MC, Formento JL, et al. EGFR in colorectal cancer: more than a simple receptor[J]. Ann Oncol, 2006, 17:962-967. doi: 10.1093/annonc/mdl037 |
|
[21]
|
Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer : a cohort study[J]. Lancet Oncol, 2005, 6:279-286. doi: 10.1016/S1470-2045(05)70102-9 |
|
[22]
|
Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study[J]. Clin Cancer Res, 2008, 14:5869-5876. doi: 10.1158/1078-0432.CCR-08-0449 |
|
[23]
|
Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines[J]. J Clin Oncol, 2006, 24: 4914-4921. doi: 10.1200/JCO.2006.06.7595 |
|
[24]
|
Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab[J]. J Clin Oncol, 2007, 25 : 3230-3237. doi: 10.1200/JCO.2006.10.5437 |
|
[25]
|
Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab[J]. J Clin Oncol, 2009, 27:5068-5074. doi: 10.1200/JCO.2008.21.3744 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
